撤回：原研药与硼替佐米仿制药治疗多发性骨髓瘤的临床观察与药物经济学评价
Retracted: Clinical Observation and Pharmacoeconomic Evaluations of Original Research Drug and Generic Drug Bortezomib in the Treatment of Multiple Myeloma.
作者信息
Healthcare Engineering Journal Of
出版信息
J Healthc Eng. 2023 Sep 27;2023:9806864. doi: 10.1155/2023/9806864. eCollection 2023.
Abstract
[This retracts the article DOI: 10.1155/2022/5201354.].
摘要
[本文撤回文章DOI: 10.1155/2022/5201354。]
相似文献
1
Retracted: Clinical Observation and Pharmacoeconomic Evaluations of Original Research Drug and Generic Drug Bortezomib in the Treatment of Multiple Myeloma.撤回：原研药与硼替佐米仿制药治疗多发性骨髓瘤的临床观察与药物经济学评价
J Healthc Eng. 2023 Sep 27;2023:9806864. doi: 10.1155/2023/9806864. eCollection 2023.
2
Clinical Observation and Pharmacoeconomic Evaluations of Original Research Drug and Generic Drug Bortezomib in the Treatment of Multiple Myeloma.硼替佐米原研药与仿制药治疗多发性骨髓瘤的临床观察及药物经济学评价。
J Healthc Eng. 2022 Mar 29;2022:5201354. doi: 10.1155/2022/5201354. eCollection 2022.
3
Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients.评价新型多发性骨髓瘤患者的硼替佐米通用分子。
Turk J Haematol. 2021 Aug 25;38(3):211-217. doi: 10.4274/tjh.galenos.2021.2020.0555. Epub 2021 May 5.
4
Retracted: Analysis of Coagulation Abnormality in Patients with Multiple Myeloma and Its Clinical Significance.撤回：多发性骨髓瘤患者凝血异常分析及其临床意义。
Evid Based Complement Alternat Med. 2023 Jun 21;2023:9874606. doi: 10.1155/2023/9874606. eCollection 2023.
5
Retracted: Efficacy Evaluation of Inflammatory Mediators in the Treatment of Multiple Myeloma with Daratumumab.撤稿：炎症介质在达雷妥尤单抗治疗多发性骨髓瘤中的疗效评估。
J Oncol. 2023 Jul 12;2023:9832530. doi: 10.1155/2023/9832530. eCollection 2023.
6
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.在新诊断的多发性骨髓瘤患者中，硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗和自体干细胞移植治疗后，用达雷妥尤单抗或观察进行维持治疗（CASSIOPEIA）：一项开放标签、随机、3 期试验。
Lancet Oncol. 2021 Oct;22(10):1378-1390. doi: 10.1016/S1470-2045(21)00428-9. Epub 2021 Sep 13.
7
Retracted: Establishment and Validation for Predicting the Death of Multiple Myeloma among Whites.撤回：白人多发性骨髓瘤死亡预测模型的建立与验证
Evid Based Complement Alternat Med. 2023 Jul 19;2023:9871636. doi: 10.1155/2023/9871636. eCollection 2023.
8
Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine.多发性骨髓瘤的管理及硼替佐米的使用：来自印度和乌克兰的观点
Front Oncol. 2016 Nov 21;6:243. doi: 10.3389/fonc.2016.00243. eCollection 2016.
9
Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.蛋白激酶 D1 预测硼替佐米为基础的治疗反应不良和生存不良，其敲低增强多发性骨髓瘤对硼替佐米的药物敏感性。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820936770. doi: 10.1177/1533033820936770.
10
Metabolic signature identifies novel targets for drug resistance in multiple myeloma.代谢特征确定了多发性骨髓瘤耐药性的新靶点。
Cancer Res. 2015 May 15;75(10):2071-82. doi: 10.1158/0008-5472.CAN-14-3400. Epub 2015 Mar 13.
本文引用的文献
1
Clinical Observation and Pharmacoeconomic Evaluations of Original Research Drug and Generic Drug Bortezomib in the Treatment of Multiple Myeloma.硼替佐米原研药与仿制药治疗多发性骨髓瘤的临床观察及药物经济学评价。
J Healthc Eng. 2022 Mar 29;2022:5201354. doi: 10.1155/2022/5201354. eCollection 2022.
Zotero 插件